RxDoctor Payments Data

Maria del Rio Giles, MD

Internal Medicine · Naples, FLNPI 1245280239

Payments from drug & device makers

$13,140in general payments, 2019–2025

Across 628 payments — averaging $20.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Pfizer$1K
  • AstraZeneca$1K
  • Amgen$1K
  • Johnson & Johnson$939
  • Abbott$740
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$12,87498%
  • Education$2062%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,140 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$360,987
Medicare patients
543
Services billed
10,300

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin182$258,474
OzempicSemaglutide132$199,772
EliquisApixaban93$138,158
TrulicityDulaglutide63$105,455
XareltoRivaroxaban60$77,320
JanuviaSitagliptin Phosphate60$76,329
FarxigaDapagliflozin Propanediol51$65,113
EntrestoSacubitril/Valsartan32$53,683
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$36,294
Janumet XrSitagliptin Phos/Metformin Hcl13$19,929
MyrbetriqMirabegron16$17,702
Tresiba Flextouch U-100Insulin Degludec18$14,591
VascepaIcosapent Ethyl14$14,475
Rosuvastatin Calcium997$13,114
SymbicortBudesonide/Formoterol Fumarate18$10,420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$392$268,697194 claims
Novo NordiskOzempic$1,715$199,772132 claims
PfizerEliquis, Prempro$1,341$143,480107 claims
Lilly USA, LLCTrulicity$632$105,45563 claims
MerckJanuvia, Janumet Xr$582$96,25873 claims
Johnson & JohnsonXarelto$939$77,32060 claims
AstraZenecaFarxiga, Symbicort$1,142$75,53369 claims
NovartisEntresto$563$53,68332 claims
GSKAnoro Ellipta$359$36,29432 claims
Astellas Pharma US IncMyrbetriq$470$17,70216 claims
AbbVieSynthroid$155$4,48474 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Naples

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →